2,644 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 2,644 shares of the medical equipment provider’s stock, valued at approximately $237,000.

Several other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after buying an additional 32,551 shares during the period. Massachusetts Financial Services Co. MA purchased a new position in shares of Lantheus during the third quarter worth about $25,955,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock worth $1,041,000 after purchasing an additional 3,772 shares in the last quarter. Empirical Asset Management LLC bought a new position in shares of Lantheus in the fourth quarter worth approximately $323,000. Finally, Focus Financial Network Inc. purchased a new stake in Lantheus in the fourth quarter valued at approximately $292,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Down 1.2 %

LNTH opened at $97.71 on Monday. The company has a market cap of $6.69 billion, a P/E ratio of 16.26 and a beta of 0.38. Lantheus Holdings, Inc. has a 12 month low of $57.92 and a 12 month high of $126.89. The business’s 50-day moving average price is $92.67 and its 200-day moving average price is $96.51.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LNTH has been the topic of a number of research analyst reports. Truist Financial increased their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. JMP Securities restated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. B. Riley cut their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a report on Friday. Finally, The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and an average target price of $129.43.

Insiders Place Their Bets

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 64,109 shares of company stock valued at $6,110,806 in the last quarter. Insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.